Genmab A/S stock is trading -38.71% below its average target price of $39.4 after dropping -5.4% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $29.0 to $51.0 per share.
The stock has a very low short interest at 0.3%, and a short ratio of 3.9. At 0.01%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 7.9% of Genmab A/S's shares being owned by this investor type.
Institutions Invested in Genmab A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Alliancebernstein L.P. | 2% | 15,237,839 | $367,993,806 |
| 2024-06-30 | Blackrock Inc. | 1% | 5,080,562 | $122,695,570 |
| 2024-06-30 | Capital International Investors | 1% | 4,227,965 | $102,105,353 |
| 2024-06-30 | Harding Loevner LLC | 0% | 2,767,805 | $66,842,489 |
| 2024-06-30 | Wellington Management Group, LLP | 0% | 2,306,920 | $55,712,117 |
| 2024-06-30 | Renaissance Technologies, LLC | 0% | 1,462,459 | $35,318,384 |
| 2024-06-30 | Citadel Advisors Llc | 0% | 1,270,888 | $30,691,944 |
| 2024-06-30 | First Trust Advisors LP | 0% | 1,208,973 | $29,196,697 |
| 2024-06-30 | Bank of America Corporation | 0% | 1,097,271 | $26,499,094 |
| 2024-06-30 | Morgan Stanley | 0% | 1,029,377 | $24,859,454 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Genmab A/S.
